✦ LIBER ✦

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

✍ Scribed by Schenk, Erin; Hendrickson, Andrea E. Wahner; Northfelt, Donald; Toft, David O.; Ames, Matthew M.; Menefee, Michael; Satele, Daniel; Qin, Rui; Erlichman, Charles

Book ID: 125358913
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 144 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9946-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of vorinostat in combina

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

✍ Schelman, William R.; Traynor, Anne M.; Holen, Kyle D.; Kolesar, Jill M.; Attia, 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 153 KB

Phase 1 study of sorafenib in combinatio

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies

✍ Shaji K. Kumar, James Jett, Randolph Marks, Ronald Richardson, Fernando Quevedo, 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 191 KB

Bortezomib in combination with celecoxib

Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

✍ John Hayslip; Uzair Chaudhary; Mark Green; Mario Meyer; Steven Dunder; Carol She 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 216 KB

A Phase I study of intermittently dosed

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

✍ Deming, Dustin A.; Ninan, Jacob; Bailey, Howard H.; Kolesar, Jill M.; Eickhoff, 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 151 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase I study of bortezomib with weekly

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

✍ S. Cresta; C. Sessa; C.V. Catapano; E. Gallerani; D. Passalacqua; A. Rinaldi; F. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 260 KB